Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease.

Publication date: Jul 29, 2024

The emergency department (ED) is a vital source of healthcare for individuals living with sickle cell disease (SCD). Prior research indicates that during the COVID-19 pandemic some individuals with SCD avoided the ED for fear of acquiring COVID-19 or delayed visiting the ED by self-management of symptoms or pain crisis at home. The purpose of the current study was to understand ED utilization rates before and during the pandemic among individuals living with SCD. We conducted a retrospective cohort study using population-based SCD surveillance systems in California, Georgia, Michigan, and Tennessee to assess the impact of the pandemic on ED utilization among people with SCD by (1) analyzing trends in monthly ED utilization from January 2019 – December 2020, with specific attention given to immediate changes at the onset of the pandemic; and (2) calculating changes in the volume of utilization by comparing the total ED visits made from March – December 2020 to the same period in 2019, both overall and by demographic characteristics. Across all states, a decline in ED utilization during the onset of the pandemic was seen, with the largest decline seen in those under age 10. By December 2020, utilization rates were higher than their lowest observed month of April 2020, but had not fully returned to pre-COVID levels. During the pandemic, ED visits in each state decreased by as much as 25%, and the number of people with any ED utilization decreased by as much as 26%. This study confirms and extends the existing literature related to the impact of the pandemic on healthcare utilization patterns in the US, in a unique population with increased healthcare needs.

Open Access PDF

Concepts Keywords
December Acute care
Georgia Adolescent
Healthcare Adult
Michigan Anemia, Sickle Cell
Pandemic Child
Child, Preschool
COVID-19
COVID-19
Emergency department
Emergency Service, Hospital
Female
Healthcare utilization
Humans
Male
Middle Aged
Pandemics
Retrospective Studies
SARS-CoV-2
Sickle cell disease
Trends
United States
Young Adult

Semantics

Type Source Name
disease MESH Emergency
disease MESH COVID-19 pandemic
disease MESH sickle cell disease
disease VO population
disease VO monthly
disease VO volume
disease VO USA
disease MESH rare disease
disease MESH complications
disease MESH infection
disease MESH stroke
disease VO organ
drug DRUGBANK Oxygen
disease IDO blood
disease MESH acute chest syndrome
disease MESH death
drug DRUGBANK Trestolone
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
drug DRUGBANK Pentaerythritol tetranitrate
disease VO Optaflu
drug DRUGBANK Ethionamide
drug DRUGBANK Tretamine
disease VO time
drug DRUGBANK Fenamole
disease IDO site
disease MESH uncertainty
disease IDO process
disease VO vaccine
disease VO ProHIBiT
disease VO age
disease IDO cell
disease MESH anemia
disease MESH Blood Cancer
disease MESH myocardial infarction
disease MESH heart failure
disease VO unvaccinated
disease VO vaccinated

Original Article

(Visited 2 times, 1 visits today)